Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $12.4M | $18.5M | $29.4M | $45.2M |
| Revenue growth | — | — | — | 49.3% | 59.0% | 53.4% |
| Gross profit | — | — | $10.1M | $15.9M | $25.3M | $38.2M |
| Gross margin | — | — | 81.8% | 85.9% | 86.1% | 84.6% |
| Operating income | — | -$3.04M | -$36.4M | -$54.5M | -$36.2M | -$26.9M |
| Operating margin | — | — | -293.9% | -294.3% | -122.9% | -59.7% |
| Net income | — | $4.77M | -$47.2M | -$59.4M | -$30.0M | -$39.2M |
| Net margin | — | — | -380.6% | -320.7% | -102.1% | -86.9% |
| EPS (diluted) | — | — | -$161.55 | -$6.77 | -$1.31 | -$1.84 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | — | -$1.74M | -$32.3M | -$50.6M | -$40.8M | -$18.0M |
| Capital expenditures | — | — | $655K | $588K | $345K | $918K |
| Free cash flow | — | — | -$33.0M | -$51.2M | -$41.2M | -$18.9M |
| Share buybacks | — | — | $232M | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.33M | $201K | $9.41M | $11.8M | $8.53M | $20.4M |
| Total assets | $252M | $251M | $22.0M | $24.6M | $24.0M | $35.3M |
| Total liabilities | $23.5M | $17.3M | $34.3M | $51.7M | $49.9M | $69.2M |
| Long-term debt | — | — | — | $0.00 | $22.1M | $33.0M |
| Shareholders' equity | $0.00 | -$130M | -$177M | -$27.1M | -$25.9M | -$33.9M |
| Retained earnings | -$21.5M | -$16.7M | -$186M | -$250M | -$280M | -$331M |
| Shares (wtd avg diluted) | — | — | 310K | 9.40M | 25.3M | 37.9M |
Every figure is extracted from TriSalus Life Sciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.